4.7 Article

Combination of 4-anilinoquinazoline and rhodanine as novel epidermal growth factor receptor tyrosine kinase inhibitors

Journal

BIOORGANIC & MEDICINAL CHEMISTRY
Volume 23, Issue 13, Pages 3221-3227

Publisher

PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.bmc.2015.04.065

Keywords

EGFR-TK inhibitors; 4-Anilinoquinazoline; Rhodanine; Structure-based design; Molecular docking

Funding

  1. National Natural Science Foundation of China [81102316]
  2. Natural Science Foundation of the Jiangsu Higher Education Institutions of China [11KJD350002]
  3. PAPD (Priority Academic Program Development of Jiangsu Higher Education Institutions)

Ask authors/readers for more resources

A type of novel rhodanine-based 4-anilinoquinazoline, which designed the combination between quinazoline as the backbone and various substituted biological rhodanine groups as the side chain, have been synthesized, and their antiproliferative activities were also evaluated firstly. These compounds displayed good antiproliferative activity and EGFR-TK inhibitory activity. Among them, compound 8d showed good inhibitory activity (IC50 = 2.7 mu M for Hep G2, IC50 = 3.1 mu M for A549) and molecular docking of 8d into EGFR TK active site was also performed, this inhibitor well fitting the active site might well explain its excellent inhibitory activity. (C) 2015 Elsevier Ltd. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available